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ABSTRACT
Small non-coding RNAs including microRNAs (miRNAs) have been recently 
recognized as important regulators of gene expression. MicroRNAs play myriads of 
roles in physiological processes as well as in the pathogenesis of a number of diseases 
by translational repression or mRNA destabilization of numerous target genes. The 
miR-106b-25 cluster is highly conserved in vertebrates and consists of three members 
including miR-106b, miR-93 and miR-25. MiR-106b and miR-93 share the same seed 
sequences; however, miR-25 has only a similar seed sequence resulting in different 
predicted target mRNAs. In this review, we specifically focus on the role of miR-
25 in healthy and diseased conditions. Many of miR-25 target mRNAs are involved 
in biological processes such as cell proliferation, differentiation, and migration, 
apoptosis, oxidative stress, inflammation, calcium handling, etc. Therefore, it is no 
surprise that miR-25 has been reported as a key regulator of common cancerous and 
non-cancerous diseases. MiR-25 plays an important role in the pathogenesis of acute 
myocardial infarction, left ventricular hypertrophy, heart failure, diabetes mellitus, 
diabetic nephropathy, tubulointerstitial nephropathy, asthma bronchiale, cerebral 
ischemia/reperfusion injury, neurodegenerative diseases, schizophrenia, multiple 
sclerosis, etc. MiR-25 is also a well-described oncogenic miRNA playing a crucial role 
in the development of many tumor types including brain tumors, lung, breast, ovarian, 
prostate, thyroid, oesophageal, gastric, colorectal, hepatocellular cancers, etc. In this 
review, our aim is to discuss the translational therapeutic role of miR-25 in common 
diseased conditions based on relevant basic research and clinical studies.
INTRODUCTION
MicroRNAs and their biogenesis
Although almost 85% of the human genome is 
known to be transcribed [1, 2], only 2% of the genome 
codes for proteins. The vast majority of the genome 
yields non-coding RNAs including long and small non-
coding RNAs [3, 4]. MicroRNAs (miRNAs, miRs) are 
a dominating class of small noncoding RNAs in most 
somatic tissues [3, 4]. They are approximately 21-25 
nucleotide in length and their major function is to mediate 
post-transcriptional gene silencing [3, 4].
A detailed description of the miRNA biogenesis is 
beyond the scope of this review. Therefore, here we just 
briefly mention some important aspects and otherwise 
refer to excellent reviews for more details (Figure 1) [4–
6]. MicroRNA genes are processed either from introns of 
protein-coding genes or dedicated miRNA gene loci [7, 
8]. An individual primary transcript can either produce a 
single miRNA or generate a miRNA cluster containing 
two or more miRNAs [7]. According to our current 
knowledge, microRNA genes are transcribed by RNA 
polymerase II as primary microRNAs (pri-microRNAs) 
(Figure 1). A typical pri-miRNA consists of a stem of 33-
35 bp, a terminal loop and single-stranded RNA segments 
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at both the 5’ and 3’ sites [5]. Pri-miRNAs are cleaved 
by the Microprocessor complex containing the RNase III 
enzyme Drosha and its essential cofactor DGCR8 and 
form precursor microRNAs (pre-miRNAs) in the nucleus 
(Figure 1) [5]. Drosha has tandem RNase III domains 
which dimerize to form one processing center [5]. The 
first RNase III domain cuts the 3’ strand of the stem of 
pri-miRNA and the second RNase III domain cuts the 5’ 
strand. The produced pre-microRNAs are double-stranded 
and approximately 70 nucleotide in length, and have a 
terminal loop [4–6] (Figure 1). These pre-miRNAs are 
subsequently transported to the cytoplasm by exportin-5 
where their terminal loops are cleaved by another RNase 
III enzyme (DICER) to form a small RNA (miR-miR*) 
duplex [4–6] (Figure 1). DICER cleavage sites are located 
at a 21-25 nucleotides distance from the 3’ end and 22 
nucleotides away from the 5’ end. This small RNA duplex 
is loaded onto an Argonaute (AGO) protein to form an 
effector complex called RNA-induced silencing complex 
(RISC) [4–6] (Figure 1). Then the two strands of the 
small RNA duplex are unwinded, and generally, only 
one strand will be the single-stranded mature microRNA 
(miR), and the other strand will be degraded (miR* or 
passenger strand) [4–6] (Figure 1). The guide strand is 
determined during the AGO loading process and generally 
becomes later the mature miR [5]. The strand at 5’ side is 
typically selected as the guide strand (miR-5p) [5]. Strand 
selection is not completely strict. Therefore, the not-
favored and less abundant passenger strand at the 3’ side 
could also be selected and act as mature miRNA (miR-
3p). Alternative strand selection (5p to 3p arm switching) 
could be tissue-specific [5]. Mature miRNAs can either 
inhibit the translation of target mRNAs or promote 
their destabilization and degradation through imperfect 
sequence-specific binding to the 3’ untranslated region 
(3’- UTR) of target mRNAs [5, 6] (Figure 1). Individual 
miRNAs may simultaneously target multiple mRNAs. 
Moreover, the expression of individual mRNAs can be 
regulated by multiple miRNAs. Therefore, miRNAs may 
act as fine tuners or as on/off switches of gene expression 
[9, 10] (Figure 1).
Classification rules of miRNAs have not yet been 
unified. It is generally considered that miRNAs with 
identical seed sequences at nucleotides 2-8 of the mature 
miRNA belong to the same miRNA (“seed”) family 
[5]. The occurrence of miRNAs belonging to distinct 
Figure 1: Maturation of miR-25. UTR: untranslated region, ORF: open reading frame.
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“seed” families within the same cluster is also commonly 
observed [5]. The seed sequence corresponds to the 3’ 
UTR of the target mRNAs and determines the possible 
mRNA targets of the miRNA [5, 7].
Since the original discovery of the first miRNA, 
lin-4 in 1993 [11] and the second miRNA, let-7 in 
Caenorhabditis elegans [11–14], the exponentially 
increasing number of studies indicate that the functions of 
miRNAs are not limited to the regulation of developmental 
events. MicroRNAs also regulate many other aspects 
of biological processes in animals and plants including 
oxidative stress, cell death, cell proliferation, etc. in 
many tissue types [15–18]. Therefore, dysregulation of 
miRNAs in pathological conditions may alter gene 
networks. Consequently, miRNA replacement or anti-
sense inhibition therapy offers a new approach to treat 
diseases by modulating gene pathways rather than single 
molecular targets [19].
MicroRNA-25
The miR-106b/25 cluster is highly conserved 
in vertebrates [20]. The three members of the cluster, 
miR-106b, miR-93, and miR-25 are located in a 515 
bp region on chromosome 7q22 in intron 13 of the 
host gene minichromosome maintenance protein 7 
(MCM7). These three miRNAs are co-transcribed with 
their host gene [6, 20, 21]. The host gene MCM7 is a 
component of the highly conserved MCM2-7 complex 
(MCM complex) [6, 20, 21]. The MCM complex is 
a member of DNA helicases which are essential in the 
initiation of DNA replication in eukaryotic cells [8]. 
MiR-106b and miR-93 share the same seed sequences; 
however, miR-25 has only a similar seed sequence 
resulting in different predicted target mRNAs [20]. In 
this review, we focus on the role of miR-25 in healthy 
and diseased conditions. The mature miR-25 (miR-25-
3p) consists of 22 nucleotides (CAUU GCAC UUGU 
CUCG GUCU GA) (ww and www.miRbase.org) and has 
1163 predicted target mRNA transcripts with conserved 
sites (TargetScanHuman version 7.1). Mature miR-25 
belongs to the evolutionary broadly conserved miR-
25-3p/32-5p/92-3p/363-3p/367-3p seed family and has 
the same predicted mRNA targets as the other miRNA 
members of this seed family (TargetScanHuman version 
7.1). The mature miR-25* (miR-25-5p) consists of 22 
nucleotides (AGGC GGAG ACAC GGGC AAUU GC) 
(https://targetexplorer.ingenuity.com/index.htm and www.
miRbase.org) and has 1868 predicted mRNA transcripts; 
however, these predicted targets are primarily false 
positives (TargetScanHuman version 7.1).
The role of miR-25 in health
It is very difficult to find literature about the 
function of miR-25 in healthy conditions in the 
PubMed database. Surprisingly, there is only a few 
relevant research paper in the PubMed database using 
the following keywords: miR-25, health; miR-25, 
physiological conditions; miR-25, normal conditions; 
miR-25, development [22–24]. Therefore, we can only 
deduce the possible roles of miR-25 in healthy conditions 
from research papers using miR-25 overexpressing or 
loss of function cells or animals. Under physiological 
conditions, mature miR-25 seems to play a crucial role 
in the regulation of developmental events [22, 23]. 
According to the AMIGO 2 gene ontology database, miR-
25 is a negative regulator of cardiac muscle growth and 
cardiac cell development (GO:0055022). Therefore, it is 
no surprise that miR-25 also play an important role in 
the development of cardiac hypertrophy and heart failure 
under pathophysiological conditions (Figure 2). Under 
normal conditions, many of miR-25 target mRNAs are 
involved in biological processes such as response to 
DNA damage, cell cycle regulation, cell proliferation, 
migration, and differentiation. In addition, many of miR-
25 target molecules can be found among extracellular 
matrix components and membrane receptors. Under 
pathophysiological conditions, miR-25 is also a well-
described oncogenic miRNA. It plays a crucial role in the 
development and spread of many tumor types including 
brain tumors, lung, breast, ovarian, prostate, thyroid, 
esophageal, gastric, colorectal, hepatocellular cancers, etc. 
Other groups of miR-25 target molecules are important 
regulators of apoptosis, autophagy, oxidative stress, 
inflammation, calcium handling, etc. These mechanisms 
could be key factors in the pathogenesis of acute 
myocardial infarction, heart failure, diabetes mellitus, 
diabetic nephropathy, tubulointerstitial nephropathy, 
asthma bronchiale, cerebral ischemia/reperfusion injury, 
neurodegenerative diseases, schizophrenia, multiple 
sclerosis, etc. In this review, we aim to provide an in-
depth discussion of the translational therapeutic role of 
miR-25 in diseased conditions based on relevant basic 
research articles and clinical studies.
The role of miR-25 in diseased conditions
Non-cancerous diseases
Cardiovascular diseases
Acute coronary syndrome
The acute coronary syndrome (ACS) is the leading 
cause of morbidity and mortality in the industrialized 
countries. ACS represents a spectrum of coronary artery 
diseases including unstable angina (UA), non-ST-
segment elevation myocardial infarction (NSTEMI) and 
ST-segment elevation myocardial infarction (STEMI) 
[25]. Acute myocardial infarction in patients is related to 
rupture-prone or vulnerable atherosclerotic plaques [26]. 
A cohort study recruiting 13 patients with non-cardiac 
chest pain and 13 patients with UA and angiographically-
proven coronary artery disease reported that members of 
the miR-106b/25 cluster were significantly elevated in 
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plasma samples of UA patients [26] (Table 1). Another 
cohort study recruiting 13 NSTEMI and 13 STEMI 
patients showed that the expression of miR-25-3p was 
significantly increased in the blood of STEMI patients 
as compared to NSTEMI patients (Table 1). According 
to the aforementioned clinical studies, circulating miR-
25 seems to be a potential biomarker in ACS. However, 
both studies have many limitations including the small 
sample size, non-diverse genetic, social, and treatment 
characteristics of ACS patients. Moreover, investigation 
of the time dependency of miR-25 upregulation in ACS 
patients would be more informative. In contrast to these 
clinical observations, the expression of miR-25 failed to 
show any change in response to 30-min ischemia and 120-
min reperfusion in isolated perfused hearts of male Wistar 
rats in our previous preclinical study [27]. Nevertheless, 
the event of 30-min coronary occlusion followed by 120-
min reperfusion was considered an early phase of cell 
injury due to necrotic and/or apoptotic processes [27]. 
Moreover, since only a single time point was used upon 
ex vivo reperfusion for heart sample harvesting, the time 
course of miRNA expression changes remained unknown 
in heart tissue and blood [27].
Left ventricular hypertrophy and heart failure
Left ventricular hypertrophy (LVH) defined as 
increase in cardiomyocyte size secondary to i) increased 
mechanical load (e.g. hypertension, valvular disease, etc.), 
ii) decreased mechanical performance (e.g. ischemic heart 
disease, myocarditis, contractile protein mutations, etc.), 
iii) increased neurohumoral activity, and iv) hereditary 
cardiomyopathies with seemingly normal performance 
and load [28–30]. During the development of LVH, a 
fetal cardiac gene program is activated by a defined set 
of transcription factors as an initially adaptive response to 
stress [29, 30]. The abnormal expression of fetal proteins 
includes contractile elements (e.g., alpha-MHC, beta-
MHC), ECM matrix components (e.g., collagens), calcium 
handling (e.g., SERCA2a) and mitochondrial proteins 
(e.g., oxidized elements of the electron transport chain), 
etc. These changes lead to a maladaptive response to stress 
resulting in the development of fibrosis, heart failure (HF) 
and fatal arrhythmias [29, 30]. From a clinical point of 
view, heart failure could be classified as heart failure with 
preserved ejection fraction (HFpEF, i.e., left vetricular 
ejection fraction (LVEF)>50%), heart failure with reduced 
ejection fraction (HFrEF, LVEF <40%) and most recently 
heart failure with mid-range ejection fraction (HFmrEF, 
LVEF 40–49%) [31].
An experimental study proved that transforming 
growth factor-β1 (TGF-β1) signaling leads to cardiac 
hypertrophy and fibrosis through a Mothers Against 
Decapentaplegic Homolog 3 (SMAD3)-dependent 
manner 20 days after transverse aortic constriction (TAC) 
Figure 2: Repression and overexpression of miR-25 in non-cancerous diseases. CNS: central nervous system, DM: diabetes 
mellitus, DNP: diabetic nephropathy, LVH: left ventricular hypertrophy, HF: heart failure, I/R: ischemia/reperfusion, PAH: pulmonary 
arterial hypertension, SCA/MJD: Spinocerebellar ataxia type 3/Machado-Joseph Disease, TIN: tubulointerstitial nephropathy. Gene 
symbols in bubbles are targets of miR-25 in multiple organs/diseases. Genes in red bubbles are targets of miR-25 in multiple diseases. 
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in SMAD3-/- and littermate control mice [32] (Table 1). 
This study also demonstrated that miR-25 transfection 
into isolated cardiac fibroblasts decreased collagen-1a2 
expression [32] (Table 1). In another study, H9c2 cells 
subjected to hypoxia/reoxygenation showed decreased 
expression of miR-25 and increased level of its direct 
target high-mobility group box 1 (HMGB1). HMGB1 
is known as a regulator of epithelial to mesenchymal 
transition and as an inflammatory as well as a pro-fibrotic 
factor [33] (Table 1). H9c2 cells showed increased levels 
of apoptosis (caspase-3) and fibrosis markers (collagen I, 
collagen III, fibronectin, TIMP1, and MM2) after hypoxia/
reoxygenation [33] (Table 1). The overexpression of miR-
25 resulted in inhibition of apoptosis and fibrosis through 
down-regulation of HMBG1 after hypoxia/reoxygenation 
in H9c2 cells [33] (Figure 2). These anti-apoptotic 
and anti-fibrotic effects of miR-25 could be further 
enhanced by a TGF-β1/SMAD3 inhibitor (SB431542) 
[33]. Therefore, miR-25 and HMGB1 seem to be early 
regulators of the TGF-β1/SMAD3 signaling pathway 
which is a key factor in the development of cardiac 
fibrosis and heart failure.
Dirkx et al. and Wahlquist et al. investigated 
the role of miR-25 in calcium handling and cardiac 
remodeling in TAC-induced LVH and HF models and 
also in human failing heart samples. However, their 
results are rather controversial [30, 34] (Table 1). Dirkx 
et al. found in a mouse model 20 days after TAC surgery 
that down-regulation of miR-25 and overactivation of the 
calcineurin/Nfat signaling resulted in overactivation of the 
Hand2 transcription factor and its target genes leading to 
cardiac fibrosis and heart failure [30] (Table 1) (Figure 
2). In contrast, Wahlquist et al. reported that cardiac 
overexpression of miR-25 could lead to LVH and HF 5.5 
months after TAC surgery in mice. Moreover, inhibition 
of miR-25 could ameliorate contractile dysfunction by 
improving sarcoendoplasmic reticulum calcium ATPase 
2 (SERCA2a) activity and Ca2+ handling [34] (Table 1) 
(Figure 2). In response to these controversial results, 
Bush et al. wrote a commentary on the potential causes 
including differences in experiment durations and 
follow-up times after TAC surgery, as well as different 
antagomiR-25 chemistries and doses [35].
Interestingly, it was found in LVH and HF 
induced by uninephrectomy and high salt (10% w/w 
NaCl) diet for 20 weeks that cardiac miR-25 level was 
significantly up-regulated and its direct target SERCA2 
level was significantly decreased [36] (Table 1) (Figure 
2). In contrast, circulating miR-25 concentration was 
significantly decreased in LVH and HF rats as compared 
to controls [36] (Table 1).
These five articles showed that miR-25 expression 
is regulated in a time-dependent manner in cardiac 
hypertrophy, fibrosis, and heart failure. MiR-25 mimics 
could play a beneficial role in early phases of cardiac 
remodeling and heart failure. However, overexpression of 
miR-25 could be detrimental due to maladaptive effects in 
chronic heart failure. Since miRNA levels in cardiac tissue 
and circulation are not always concordant, caution must be 
exercised during the utilization of miRs as diagnostic or 
prognostic biomarkers.
Arrhythmias
It is also well-known that increased sarcoplasmic 
reticulum (SR) Ca2+-leak via ryanodine receptor type-
2 (RyR2) contributes to the pathogenesis of atrial 
fibrillation (AF). Interestingly, the expression of miR-25 
was decreased in atria of patients with paroxysmal atrial 
fibrillation (PAF) compared with patients with sinus 
rhythm [37] (Table 1). Moreover, this study showed that 
miR-106b-25−/− mice expressed increased atrial RyR2 
protein levels as well as SR Ca2+-leak, and were more 
prone to atrial ectopy than wild-type littermates [37] 
(Table 1) (Figure 2).
Hypercholesterolemia
Hypercholesterolemia is a well-known risk factor 
for cardiovascular diseases, and it leads to increased 
oxidative/nitrative stress in the myocardium [38]. 
Experimental data are very limited on the regulatory role 
of miRNAs in hypercholesterolemia-induced cardiac 
pathologies. We have previously shown that diet-induced 
hypercholesterolemia in male Wistar rats (2% cholesterol- 
and 0.25% sodium cholate-enriched diet for 12 weeks) 
leads to the down-regulation of miR-25 in the myocardium 
[39] (Table 1). Subsequently, the superoxide-generating 
NADPH oxidase 4 (NOX4) which is a direct target of 
miR-25, was up-regulated in the myocardium. In the same 
study, cardiac oxidative/nitrative stress was also increased 
leading to diastolic dysfunction in hypercholesterolemic 
rats [39] (Table 1) (Figure 2). Moreover, knock-down of 
miR-25 could significantly increase the oxidative stress 
and NOX4 protein levels in neonatal rat cardiomyocytes 
24 hours after transfection of a miR-25 inhibitor proving 
the direct link between miR-25 and NOX4 expression [39] 
(Table 1) (Figure 2). However, in another study it was 
reported that oxidative stress induced by 2 or 3 hours of 
H2O2-incubation (500 μM) could significantly up-regulate 
miR-25 expression in H9c2 embryonic rat ventricular 
myocytes [40]. Furthermore, the overexpression of 
miR-25 markedly reduced the oxidative stress-induced 
apoptosis in H9c2 cells by down-regulating mitochondrial 
calcium uniporter (MCU) which has been shown to control 
the Ca2+ flux through the inner mitochondrial membrane 
[40] (Figure 2).
Intimal hyperplasia
Thrombospondin-1 is known as a key factor in 
vascular smooth muscle cell (VSMC) migration after 
vascular injury. It has been reported that the expression 
of miR-25-5p beyond other miRNAs was significantly 
decreased in human VSMCs in response to a 6-hour 
thrombospondin-1 treatment [41] (Table 1). This study 
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Table 1: The role of miR-25 in cardiovascular and renal diseases
Disease Species and tissue or cell type
Alteration of miR-
25 expression
Method 
for miR-25 
detection
Target 
gene
Biological 
function
Method 
for target 
validation
Sample 
size in 
clinical 
studies
Ref.
1 ACS - NSTEMI vs. STEMI
Human BP 
(American) up-regulation
Qiagen 
miRNeasy kit N/A N/A N/A
9 STEMI 
vs. 
4 NSTEMI
[25]
2 ACS - UA Human BP (Chinese)
up-regulation (miR-
106b-25 cluster)
Taqman 
low density 
miRNA array
N/A N/A N/A 13 UA vs. 13 CONT [26]
3 H/R H9c2 cells(24 h I/1 h R) down-regulation qRT-PCR HMGB1 inflammation
DLRA, miR-
25 TF N/A [33]
4 LVH and HF
heart of TAC mice
(4,8,10 wk) and 
human HF
down-regulation
Affymetrix 
GeneChip 
Mouse Gene 
St 1.0 Array, 
Northern blot, 
qRT-PCR
Hand2 hypertrophy and fibrosis
LRA, 
MHC-Hand2 
TG mice, 
miR-25 TF, 
antagomiR-25
N/A [30]
5 LVH and HF
heart of SMAD3-/- 
TAC mice
(10-20 days),
cardiac FB
up-regulation miRNA array, qRT-PCR Col1a2 fibrosis miR-25 TF N/A [32]
6 LVH and HF
heart of TAC 
mice (22 wk), 
and human HF, 
HEK293 cells and 
RCm
up-regulation miRNA array, qRT-PCR SERCA2a
calcium 
handling
LRA, miR-25 
OE mice, 
SERCA2a 
KO mice, 
antagomiR-25 
assay
N/A [34]
7 LVH and HF
uninephrectomized 
and salt-fed rat 
myocardium (20 
wk) and plasma
up-regulation 
(myocardium)down-
regulation (plasma)
qRT-PCR SERCA2a calcium handling Western blot N/A [36]
8 Hyper-cholesterolemia
rat myocardium (12 
wk) and RCm down-regulation
Agilent’s 
microRNA 
complate 
labeling and 
hyb system, 
qRT-PCR
NOX4 oxidative stress LRA N/A [39]
9 Paroxysmal atrial fibrillation
human RA 
(German), heart 
of miR-25/106b-/- 
mice, H9c2 cells
down-regulation qRT-PCR RyR2 calcium handling LRA
8 pAF vs. 
10 CONT [37]
10
Atherosclerosis 
and vascular 
remodelling
human aortic 
VSMCs
down-regulation of 
miR-25-5p
Affymetrix 
GeneChip 
microRNA 
Array and 
qRT-PCR
N/A N/A N/A N/A [41]
11 Intracranial aneurysm
Human BP 
(Chinese) up-regulation
Agilent’s 
microRNA 
complate 
labeling and 
hyb system, 
qRT-PCR
N/A N/A N/A 40 IA vs. 20 CONT [42]
12
Pulmonary 
arterial 
hypertension
human PASMCs, 
rat up-regulation
Affymetrix 
GeneChip 
miRNA 
4.0 Array, 
Northern blot, 
qRT-PCR
MCU apoptosis
LRA,
MCU OE, 
antagomiR-25 
in rats
6 PAH vs. 
3 CONT [43]
(Continued )
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Disease Species and tissue or cell type
Alteration of miR-
25 expression
Method 
for miR-25 
detection
Target 
gene
Biological 
function
Method 
for target 
validation
Sample 
size in 
clinical 
studies
Ref.
13 T1DM
male Wistar rats 
(3 wk HFD+STZ), 
INS-1 cells
up-regulation
Exiqon 
miRCURY 
LNA array,
qRT-PCR
insulin glucose homeostasis
LRA, miR-25 
TF N/A [45]
14 T1DM
human BS 
(European 
multicenter and 
Danish cohort)
up-regulation
Illumina 
Solexa 
Sequencing
N/A N/A N/A
275 
European 
T1DM, 
129 Danish 
T1DM and 
151 CONT
[46]
15 TIN HK-2 cell line (human)
down-regulation 
(miR-106b-25 
cluster)
Exiqon 
miRCURY 
LNA array,
qRT-PCR
TGFBR2 fibrosis WB, miR-106b TF N/A [20]
16 DNP
mesangial cells 
from male SD rats
(12 wk, STZ)
down-regulation qRT-PCR NOX4 oxidative stress LRA N/A [48]
17 IgA NP human urine (Chinese) up-regulation
Agilent 
human 
miRNA 
microarray 
V19.0,
qRT-PCR
N/A N/A N/A
93 IgA 
NP vs. 
82 CONT
[49]
Abbreviations: ACS: acute coronary syndrome, BP: blood plasma, BS: blood serum, CONT: control, DLRA: dual luciferase reporter assay, DNP: diabetic 
nephropathy, FB: fibroblast, IF: immunofluorescence, HF: heart failure, HFD: high fat diet, H/R: hypoxia/reoxygenation, IA: intracranial aneurysm, 
IgA NP: IgA nephropathy, IH: immunohistochemistry, LRA: luciferase reporter assay, LVH: left ventricular hypertrophy, KO: knock out, NSTEMI: non 
ST-elevation myocardial infarction, OE: overexpression, pAF: paroxysmal atrial fibrillation, PAH: pulmonary arterial hypertension, PASMCs: pulmonary 
artery smooth muscle cells, RA: right atrium, RCm: rat cardiomyocytes, SD: Sprague Dawley, STEMI: ST-elevation myocardial infarction, STZ: 
streptozotocin, T1DM: type 1 diabetes mellitus, TAC: transverse aortic constriction, TIN: tubulointerstitial nephropathy, TF: transfection, TG: transgene, 
UA: unstable angina, VSMC: vascular smooth muscle cell, WB: Western blot, wk: week. The abbreviations in bold are considered as gold standard 
methods for miRNA target validation.
may suggest that miR-25-5p and other altered microRNAs 
might contribute to the development of atherosclerosis and 
intimal hyperplasia.
Intracranial aneurysm
Interestingly, a clinical cohort study enrolling 40 
patients with intracranial aneurysm (IA), 20 healthy 
volunteers and an independent validation cohort including 
93 IA patients reported that increased plasma miR-25 level 
might be a potential biomarker for intracranial aneurysm 
[42] (Table 1).
Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is an 
obstructive, arterial vasculopathy characterized by 
excessive pulmonary artery smooth muscle cell (PASMC) 
proliferation and migration [43]. It leads to vascular 
stiffening, vasoconstriction, mitochondrial and metabolic 
dysfunction and finally right ventricular failure [43]. A 
study proved that overexpression of miR-25 in human 
PASMC samples resulted in decreased expressions of 
mitochondrial calcium uniporter (MCU) and cAMP 
response element binding protein (CREB1). These 
gene expression alterations resulted in mitochondrial 
and metabolic dysfunction and a cancer-like phenotype 
with apoptosis resistance [43] (Table 1) (Figure 2). The 
downregulation of MCU by miR-25 has also been found 
in cardiomyocytes by Pan et al. [40] (Table 1) (Figure 2).
Diabetes mellitus
Diabetes mellitus is a heterogeneous chronic 
metabolic disorder characterized by hyperglycemia as a 
common feature resulting from impaired insulin secretion, 
insulin resistance, or both [44]. Type-2 diabetes mellitus 
(T2DM) accounts for more than 85% of all diabetes cases, 
and its incidence is continuously rising worldwide [44]. 
It has been reported that high-fat diet and streptozotocin-
induced T2DM lead to increased pancreatic miR-25 
expression and decreased mRNA expression of its direct 
target insulin stabilizing polypyrimidine tract binding 
protein 1 (PTBP1) which resulted in decreased insulin 
translation and secretion [45] (Table 1) (Figure 2). 
Moreover, a clinical study enrolling two T1DM cohorts 
(n=275 for European T1DM children and 129 for Danish 
T1DM children) and one control group (n=151) reported 
that serum miR-25 level was significantly increased in 
T1DM children and was inversely correlated with residual 
beta cell function [46] (Table 1).
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Chronic kidney disease
Chronic kidney disease is often associated with 
tubulointerstitial fibrosis leading to progressive functional 
deterioration [20]. It has been demonstrated that all 
members of the miR-106b-25 cluster including miR-106b, 
miR-93 and miR-25 were significantly down-regulated 
after 48 h TGF-β1 treatment (5 ng/ml) in human kidney 
proximal tubular epithelial cell line (HK-2) [20] (Table 
1). Bioinformatics analysis identified the TGF-β type-II 
receptor as a potential target of the miR-106b-25 cluster. 
Indeed, miR-106b transfection resulted in decreased 
expression of TGF-β type II receptor in HK-2 cells [20] 
(Table 1). Hence, the repression of miR-25 and miR-106b 
may be a key factor in the development of TGF-β1-mediated 
fibrosis both in the kidney and the heart [32] (Table 1).
Diabetes mellitus is one of the leading causes of 
end-stage renal disease [47]. NADPH oxidase-derived 
superoxide seems to play a key role in hyperglycemia-
induced oxidative stress in diabetic nephropathy [48]. 
MiR-25 expression was significantly reduced and NOX4 
mRNA and protein levels were increased in the kidney 
of streptozotocin-induced diabetic rats and high glucose-
treated mesangial cells [45] (Table 1). Furthermore, 
mesangial cells transfected with antagomiR-25 showed 
significantly increased NOX4 mRNA and protein levels 
[48] (Table 1) (Figure 2). These results are in line with 
our findings in the hearts of hypercholesterolemic 
rats with increased cardiac tissue oxidative stress and 
diastolic dysfunction in the presence of decreased miR-25 
expression [39] (Table 1) (Figure 2). Therefore, the miR-
25-NOX4-oxidative stress axis seems to play a common 
role in kidney and heart disease.
IgA nephropathy is the most common primary 
glomerulonephritis leading to end-stage renal disease 
[49]. A clinical cohort study recruiting 3 control and 
9 IgA nephropathy patients showed that miR-25 was 
significantly increased in the urinary sediment derived 
mainly from urinary erythrocytes of IgA nephropathy 
patients [49].
Non-cancerous nervous system diseases
Cerebral ischemia/reperfusion injury
Cerebral ischemia is a condition when blood and 
oxygen supply to the brain tissues is insufficient [50, 
51]. Rapid reperfusion is still the gold standard therapy 
for cerebral ischemia and other types of ischemic organ 
damages including e.g., ischemic stroke, myocardial 
infarction and organ transplantations [50]. However, 
reperfusion causes further tissue injuries due to increased 
oxidative/nitrative stress leading to mitochondrial 
dysfunction, lipid peroxidation, protein oxidation, DNA 
damage and finally cell death [38]. MiR-25 was repressed 
in a model of 48-h oxygen-glucose deprivation and 48-h 
reoxygenation in human neuroblastoma SH-SY5Y and 
IMR-32 cells [50] (Table 2). Furthermore, overexpression 
of miR-25 protected cells against apoptosis induced by 
oxygen-glucose deprivation/reoxygenation possibly 
through the Fas/FasL pathway [50] (Table 2) (Figure 
2). This protective effect of miR-25 against apoptosis in 
human neuroblastoma SH-SY5Y and IMR-32 cells are 
in concordance with the findings of Pan et al. reported 
in H9c2 embryonic rat ventricular myocytes [40, 50] 
(Table 1-2) (Figure 2). Interestingly, 10-Hz repetitive 
transcranial magnetic stimulation was reported to improve 
proliferation of adult neural stem cells 7 days after focal 
cerebral ischemia in the subventricular zone in rats [52] 
(Table 2) Moreover, the beneficial effect of repetitive 
transcranial magnetic stimulation was associated with 
the overexpression of miR-25 and repression of its direct 
target p57 (CDKN1C). It is a member of the cyclin-
dependent kinase (CDK) inhibitors blocking the cell cycle 
in G1/S phase [49] (Table 2) (Figure 2). Interestingly, a 
study related to CNS development in zebrafish embryos 
has also shown that scratch2 transcription factor could 
block the cell cycle re-entry by maintaining high levels 
of CDKN1C (p57) via the repression of miR-25 in 
postmitotic primary neurons [53] (Table 2) (Figure 2).
Spinocerebellar ataxia type 3
Spinocerebellar ataxia type 3/Machado Joseph 
disease (SCA3/MJD) is the most common type of inherited 
spinocerebellar ataxia forms [48], and its symptoms include 
cerebellar ataxia, spasticity, parkinsonism, dystonia, eye 
movement disorders, sensory loss, muscle weakness, 
fasciculation, etc. [54]. SCA/MJD is also known as a 
polyglutamine (polyQ) disease caused by glutamine-
encoding CAG nucleotide expansions within endogenous 
human genes resulting in an abnormal polyQ tract in 
the polyQ-expanded mutant ataxin-3 protein [48]. This 
abnormal ataxin-3 protein aggregates in the nucleus 
and adjacent areas of the affected neurons exacerbating 
cell death [51]. Overexpression of miR-25 was found to 
suppress apoptosis in SCA/MJD model cells possibly 
by the posttranscriptional reduction of polyQ-expanded 
ataxin-3 protein levels [51] (Table 2) (Figure 2). Indeed, the 
same research group reported in a clinical cohort study that 
serum level of miR-25 was significantly lower in SCA3/
MJD patients (n=35) as compared to healthy controls 
(n=25) [51] (Table 2). Moreover, serum miR-25 level 
was significantly decreased in SCA3/MJD patients with a 
course of disease more than 6 years as compared to those 
patients with shorter disease course [51].
Multiple sclerosis
Multiple sclerosis (MS) is an inflammatory and 
subsequently degenerative disease of the central nervous 
system (CNS). It is defined by focal demyelinated lesions 
in the white matter of the brain and spinal cord [55]. A 
clinical study enrolling 12 MS relapsing–remitting patients 
in stable condition and 14 healthy controls revealed that 
members of the miR-106b-25 cluster were down-regulated 
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in CD4+CD25highCD127dim/−T regulatory cells of MS patients 
[56] (Table 2).
Schizophrenia
Schizophrenia is a chronic severe neuropsychiatric 
disorder with strong genomic and environmental risk 
factors. The expression of miR-25, a transcriptional 
regulator of SERCA2 was downregulated in a mouse 
model of schizophrenia [57] (Table 2) (Figure 2). The 
22q11 deletion syndrome (22q11DS) is one of the 
strongest known genetic risks for schizophrenia [54]. A 
mouse model of 22q11DS had an age-dependent increase 
in hippocampal long-term potentiation (LTP), a form of 
synaptic plasticity needed in learning and memory [57, 
58]. In this mouse model of schizophrenia, the expression 
of SERCA2 is increased resulting in elevated loading 
of the endoplasmic reticulum with Ca2+ and enhanced 
neurotransmitter release as well as increased LTP [57, 58]. 
A study has found that haploinsufficiency of DGCR8; a 
miRNA biogenesis gene in the 22q11DS disease-critical 
region led to synaptic SERCA2 overexpression and 
increased LTP [57]. Moreover, SERCA2 was elevated in 
human brain samples with schizophrenia [57] (Table 2) 
(Figure 2).
Neurotoxicity by dioxins
Acetylcholinesterase (AChE) plays a central role in 
cholinergic neurotransmission in central and peripheral 
nervous systems by hydrolysation of the neurotransmitter, 
acetylcholine [56]. Dioxins were shown to decrease 
AChE expression directly in neuroblastoma cells and 
immune cells by transcriptional regulation via aryl 
hydrocarbon receptor and by post-translational regulation 
via microRNAs including miR-25 [59]. Proposed 
mechanisms of dioxin toxicity are reviewed in detail by 
Xie et al. [59].
Asthma bronchiale
A study using human tracheal smooth muscle cells 
revealed that miR-25 was significantly down-regulated 
after exposing cells to pro-inflammatory cytokines 
including IL-1β, TNF-α, and IFN-γ [60]. In this study, the 
repression of miR-25 resulted in the overexpression of its 
direct target Krüppel-like factor 4 (KLF4). KLF4 is known 
as an inhibitor of smooth muscle-specific gene expression 
and mediator of inflammation [60] (Table 2) (Figure 2).
Cancerous diseases
Cancerous nervous system diseases
Glial tumors
Astrocytoma originating from astrocytic glial cells 
is the most common type of primary tumor type in the 
central nervous system [61]. Anaplastic astrocytoma (AA) 
is a high-grade malignant glioma (grade III according 
to the WHO classification) developing from low-grade 
diffuse astrocytoma (DA; grade II) and progressing into 
glioblastoma of grade IV [61]. Glioblastoma multiforme 
is the most malignant and aggressive form of gliomas 
showing a median survival time of 15 months after 
standard therapy [62]. Few studies have investigated 
the role of miR-25 in the development of gliomas [62–
66] (Table 3). Most of them indicate that miR-25 is 
overexpressed, and behave as an oncomiR during the 
development of gliomas [62, 63, 65, 66] (Table 3). These 
results suggest that miR-25 has mRNA targets directly 
or indirectly regulating pathways related to cell cycle 
or cell death. Zhang et al. reported that miR-25 was 
overexpressed in more than 90% of human glioma tissues 
(grade II-IV) and 60% of human glioma cell lines [62]. 
Furthermore, miR-25 has been shown to increase glioma 
cell proliferation by directly targeting the CDK inhibitor 
type 1C (CDKN1C or p57) resulting in an increase of 
S/M phase cells and a decrease of G0/G1 phase cells 
[62] (Table 3) (Figure 3). The miR-25 and CDKN1C 
(p57) axis seem to play a central role in the regulation 
of cell cycle re-entry not only in glioblastoma and 
cancerous cell proliferation but also in healthy conditions 
and after ischemia/reperfusion injury as mentioned in 
the previous section [52, 53, 62]. In accordance with 
the findings of Zhang et al., another study has found 
that miR-25 was overexpressed in human astrocytoma 
samples and glioblastoma cell lines leading to tumor 
growth and invasion by directly targeting neurofilament 
light polypeptide (NEFL) which was an inhibitor of the 
mammalian target of rapamycin (mTOR) cell proliferation 
pathway [65] (Table 3) (Figure 3). Interestingly, a network 
analysis study investigating transcription factors, miRNAs 
and their target genes in human anaplastic astrocytoma 
reported that miR-25 might target tumor suppressor p53 
and it could be regulated by another tumor suppressor, the 
phosphatase and tensin homolog (PTEN) [61] (Table 3) 
(Figure 3). In contrast, only one study has reported that 
overexpression of miR-25 could suppress glioblastoma 
growth in vivo and in vitro by a p53 tumor suppressor-
dependent mechanism [64] (Table 3) (Figure 3). In this 
study, miR-25 was identified as a miRNA repressed 
indirectly by p53 through the transcriptional regulators of 
the P53 gene, E2F1 (also called retinoblastoma binding 
protein-3) and MYC [64] (Table 3) (Figure 3). In addition, 
overexpression of miR-25 resulted in the downregulation 
of its direct targets MDM2 and TSC1. Both targets are 
negative regulators of the p53 tumor suppressor and the 
mTOR cell proliferation pathway, respectively [64]. In that 
article, the authors speculated on that overexpression of 
miR-25 could stabilize p53 tumor suppressor expression 
through activation of mTOR pathway by targeting TSC1. 
However, this finding is controversial to the results of 
Peng et al. [64, 65].
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Retinoblastoma
Retinoblastoma (RB) is a typical malignant tumor 
appearing in children [67]. A clinical pilot study with a 
very limited sample size enrolling 3 healthy and 3 RB 
retina samples has reported that miR-25 was significantly 
overexpressed in RB [67] (Table 3) (Figure 3). After 
miRNA-target analysis using experimentally validated 
databases and pathway enrichment analysis, the apoptosis 
regulator BCL2L1 seemed to be a potentially important 
target of miR-25 in RB [67] (Table 3) (Figure 3).
Lung cancer
Non-small cell lung cancer
Lung cancer is the leading cause of tumor-related 
mortality worldwide [68]. Non-small cell lung cancer 
Table 2: The role of miR-25 in non-cancerous nervous system diseases
Disease
Species and 
tissue or cell 
type
Alteration 
of miR-25 
expression
Method 
for miR-25 
detection
Target 
gene
Biological 
function
Method 
for target 
validation
Sample size 
in clinical 
studies
Ref.
1 Cerebral I/R
SH-SY5Y and 
IMR-32 cells 
(48 h OGD/ 
48 h R)
up-
regulation qRT-PCR Fas apoptosis
DLRA,
miR-25 TF, 
WB
N/A [50]
2 Cerebral I/R brain of male SD rats (7 days)
up-
regulation qRT-PCR p57
cell cycle 
arrest
antagomiR-25, 
WB N/A [52]
3 CNS development
postmitotic 
primary neurons 
of zebrafish 
embryos
down-
regulation qRT-PCR p57
cell cycle 
arrest DLRA N/A [53]
4 SCA3/MJD
SCA/MJD 
model cells, 
293T and
SH-SY5Y cells
up-
regulation qRT-PCR ATXN3 ataxia DLRA N/A [51]
5 SCA3/MJD human BS (Chinese)
down-
regulation qRT-PCR N/A N/A N/A
35 SCA/MJD 
vs. 25 CONT [54]
6 MS human BP, T-cells (Italian)
down-
regulation
(miR-
106b-25 
cluster)
Agilent 
human 
miRNA 
microarray 
V2.0,  
qRT-PCR
N/A N/A N/A 12 MS vs 14 CONT [56]
7 Schizophrenia
mouse 
hippocampus 
(8-10, 16-20 
wk) human 
brain tissues
down-
regulation
Agilent 
mouse 
miRNA 
microarray, 
qRT-PCR
SERCA2 calcium handling
miR-25 viral 
infection
17 
schizophrenia 
vs. 22 CONT
[57]
8 Asthma bronchiale
human tracheal 
SMCs
down-
regulation
miRNA 
array KLF4 inflammation
WB, anti-
miR-25 TF N/A [60]
9 CF human BS (Australian)
up-
regulation
Qiagen 
miRNA PCR 
array for 
serum and 
plasma
N/A N/A N/A
52 CF 
with liver 
disease50 CF 
without liver 
disease
[153]
10 Liver regeneration
male SD rats 
(6, 12, 24, 36 h)
up-
regulation
Agilent rat 
miRNA 
array, V16, 
8X15k
RB1, 
KAT2B
cell cycle 
arrest LRA, IH, WB N/A [149]
Abbreviations: BP: blood plasma, BS: blood serum, CF: cystic fibrosis, CNS: central nervous system, CONT: control, DLRA: dual 
luciferase reporter assay, h: hour, IF: immunofluorescence, IH: immunohistochemistry, I/R: ischemia/reperfusion, LRA: luciferase 
reporter assay, KO: knock out, MS: multiple sclerosis, OE: overexpression, OGD: oxygen glucose deprivation, R: reoxygenation, SCA/
MJD: Spinocerebellar ataxia type 3/Machado-Joseph Disease, SD: Sprague Dawley, SMCs: smooth muscle cells, TF: transfection, TG: 
transgene, WB: Western blot, wk: week. The abbreviations in bold are considered as gold standard methods for miRNA target validation.
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(NSCLC) accounts for 80-85% of all lung cancer cases, 
and its 5-year survival rate is about 15% [68]. Savita et 
al. reported that the overexpression of the miR-106b-25 
cluster could directly suppress the ubiquitin ligase 
β-TRCP2 gene expression leading to decreased Snail 
degradation in H1299 non-small cell lung cancer cells [69] 
(Table 4) (Figure 3). Snail has been reported to positively 
regulate cell adhesion and migration as well as invasion 
[70, 71]. Xiang et al. demonstrated that the oncogenic 
effect of miR-25 is partially due to direct targeting and 
repressing F-box and WD repeat domain-containing 7 
(FBXW7 also known as FBW7) in human NSCLC tissue 
samples and cell lines [68] (Table 4) (Figure 3). FBXW7 
is a putative tumor suppressor in human tumorigenesis 
due to its ability to recognize and bind target proteins 
for ubiquitination and degradation [68]. Other studies 
suggested that the overexpression of miR-25 could reduce 
apoptosis by different mechanisms in human NSCLC cells 
and cell lines [72, 73] (Table 4). Wu et al. reported that 
miR-25 directly targeted the modulator of the apoptosis 
1 (MOAP1) gene which was a Bax-associated protein 
containing BH3-like motif and mediating caspase-
dependent apoptosis [72] (Table 4) (Figure 3). Chen 
et al. found that overexpression of miR-25 directly 
repressed the regulator of G protein signaling 3 (RGS3)
gene which potentially could play a role in apoptosis as 
Table 3: The role of miR-25 in cancerous nervous system diseases
Disease
Species 
and tissue 
or cell type
Alteration 
of miR-25 
expression
Method 
for miR-25 
detection
Target gene Biological function
Method 
for target 
validation
Sample size 
in clinical 
studies
Ref.
1 GBM
human 
brain tumor 
tissue 
(American)
up-
regulation
Agilent human 
miRNA 
microarray 
version 1,  
qRT-PCR
N/A N/A N/A
24 CNS 
tumors vs. 
8 CONT
[66]
2 GBM
human 
GBM 
sample 
(Chinese), 
GMB cell 
lines
up-
regulation qRT-PCR NEFL apoptosis
LRA,
WB
44 GBM vs. 
20 CONT [65]
3 GBM
human 
GBM 
sample 
(Chinese), 
human 
GBM cell 
lines
up-
regulation qRT-PCR p57
cell cycle 
arrest
LRA,
miR-25 TF
35 GBM vs. 
5 CONT [62]
4 GBM
human 
GBM 
sample 
(dataset)
up-
regulation
dataset 
analysis p53
apoptosis, 
cell cycle 
arrest
network 
analysis N/A [61]
5 GBM
human 
GBM cell 
lines, mice 
(35 days)
up-
regulation
Nanostring 
assay,
qRT-PCR
MDM2, 
TSC1 apoptsosis
LRA,
miR-25 TF, 
WB
N/A [64]
6 RB
human RB 
sample 
(Chinese)
up-
regulation
Agilent human 
miRNA 
microarray 2k
Bcl2L1 apoptosis
exp. 
validated 
databases
3 RB vs.
3 CONT [67]
Abbreviations: CONT: control, DLRA: dual luciferase reporter assay, GBM: glioblastoma multiforme, IF: 
immunofluorescence, IH: immunohistochemistry, LRA: luciferase reporter assay, KO: knock out, OE: overexpression, 
RB: retinoblastoma, TF: transfection, TG: transgene, WB: Western blot. The abbreviations in bold are considered as gold 
standard methods for miRNA target validation.
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a cancer suppressor [73] (Table 4) (Figure 3). He et al. 
reported that radiotherapy-resistant NSCLC human tissues 
overexpressed miR-25 as compared to radiosensitive or 
non-cancerous tissues [74] (Table 4). In addition, miR-
25 overexpression correlated negatively with its direct 
BTG anti-proliferation factor 2 (BTG2) expression 
(Table 4) (Figure 3). BTG2 has been shown to inhibit cell 
proliferation and invasion by repressing cyclin D1, matrix 
metalloproteinase-1 and metalloproteinase-2 in human 
lung cancer cells [74]. Interestingly, down-regulation of 
miR-25 by antagomiR-25 treatment was shown to inhibit 
NSCLC cell proliferation and induce G1 cell cycle arrest 
possibly through indirect down-regulation of the cell 
division cycle 42 (CDC42) gene [75] (Table 4) (Figure 4).
REV3Lp is the catalytic subunit of DNA polymerase 
zeta playing a crucial role in genome stability in 
mammalian cells. A study investigating the polymorphism 
of REV3Lp in lung cancer susceptibility in Chinese Han 
population (n=500 lung cancer patients and 517 cancer-
free control) revealed that (3’UTR) 460 T>C single 
Figure 3: Overexpression of miR-25 in cancerous diseases. EAC/BE: esophageal adenocarcinoma/Barrett esophagus, ESCC: 
esophageal squamous cell carcinoma, CAC: cholangiocarcinoma, CRC: colorectal cancer, GC: gastric cancer, GBM: glioblastoma 
multiforme, HCC: hepatocellular carcinoma, NSCLC: non-small cell lung carcinoma, OVC: ovarian cancer, PC: prostate cancer, PTC/FTC: 
papillary thyroid carcinoma/follicular thyroid carcinoma, RB: retinoblastoma. Gene symbols in bubbles are targets of miR-25 in multiple 
organs/diseases. Genes in red bubbles are targets of miR-25 in multiple diseases.
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Table 4: The role of miR-25 in lung cancer
Disease
Species and 
tissue or cell 
type
Alteration 
of miR-25 
expression
Method 
for miR-25 
detection
Target 
gene
Biological 
function
Method 
for target 
validation
Sample size in 
clinical studies Ref.
1 NSCLC H1299 cells
up-
regulation 
of miR-
106b and 
miR-93
qRT-PCR beta-TRCP2 ubiquitination LRA N/A [69]
2 NSCLC
human 
NSCLC tissue 
(Chinese), 
human NSCLC 
cell lines
up-
regulation qRT-PCR FBXW7
cell cycle 
arrest
LRA, miR-25 
TF, WB
16 NSCLC vs.
16 CONT [68]
3 NSCLC
human BP 
(Chinese), 
human NSCLC 
cell lines
up-
regulation qRT-PCR MOAP1 apoptosis
LRA, miR-25 
TF, MOAP1 
OE or KO, 
anatgomiR-25 
in vivo
81 NSCLC vs.
41 CONT [72]
4 NSCLC
human 
NSCLC tissue 
(Chinese), 
human NSCLC 
cell line
up-
regulation qRT-PCR RGS3 apoptosis DLRA, WB
35 NSCLC vs. 
ADJNTT [73]
5 NSCLC
human 
NSCLC tissue 
(Chinese), 
human NSCLC 
cell line
up-
regulation qRT-PCR BTG2
proliferation 
inhibitor
LRA, 
antagomiR-25 
and miR-25 TF 
in vitro, WB
60 NSCLC vs.
32 CONT [74]
6 NSCLC
human 
NSCLC tissue 
(Chinese), 
human NSCLC 
cell line, 
female nude 
mice (35 days)
down-
regulation qRT-PCR CDC42 proliferation
LRA, 
antagomiR-25 
TF in vivo, 
CDC42 OE, 
WB
11 NSCLC vs. 
ADJNTT [75]
7 NSCLC
human BS 
(American, 
Chinese)
up-
regulation
Taqman 
low density 
array, qRT-
PCR
N/A N/A N/A
221 NSCLC vs. 
161 CONT (56 
benign nodules)
[77]
8 NSCLC
human NSCLC 
tissue, human 
BP (Chinese)
up-
regulation qRT-PCR N/A N/A N/A
100 female 
NSCLC  
(non-smoking)
[63]
9 SCLC
human 
SCLS tissue 
(Chinese), 
human SCLC 
cell lines
up-
regulation qRT-PCR CDK2 proliferation
LRA, 
anatgomiR-25 
in vitro, WB
9 SCLC vs. 
ADJNTT [80]
Abbreviations: ADJNTT: adjacent non-tumorous tissue, BP: blood plasma, CONT: control, DLRA: dual luciferase reporter assay, 
IF: immunofluorescence, IH: immunohistochemistry, LRA: luciferase reporter assay, KO: knock out, NSCLC: non-small cell lung 
carcinoma, OE: overexpression, SCLC: small cell lung carcinoma, TF: transfection, TG: transgene, WB: Western blot. The abbreviations 
in bold are considered as gold standard methods for miRNA target validation.
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nucleotide polymorphism (rs465646) showed a strong 
association with lung cancer development [76]. The T 
allele demonstrated a stronger binding affinity for miR-25 
and miR-32 which could down-regulate the endogenous 
tumor suppressor REV3L [76]. Furthermore, an ethnically 
diverse multicenter case-control study recruiting 221 
NSCLC patients, 161 controls and 56 patients with benign 
nodules from China and America reported that serum 
levels of miR-25 and other four miRNAs (miR-483-5p, 
miR-193a-3p, miR-214 and miR-7) were significantly 
elevated irrespective of ethnicity groups [77] (Table 4). A 
clinical study enrolling 100 Chinese female non-smoking 
lung adenocarcinoma patients found that increased plasma 
miR-25 levels positively correlated with the mortality rate, 
advanced disease stage, regional and distant metastasis 
at diagnosis as well as epithelial growth factor receptor 
(EGFR) mutation status [63] (Table 4). Another clinical 
study investigating circulating miRNA levels in response 
to chemotherapy or operation in Russian lung cancer 
patients (n=23, T1-3N0-3M0) showed that the plasma 
concentration of miR-25 did not change 15 days after 
surgery or within 30 days after completing two courses of 
paclitaxel-carboplatin chemotherapy as compared to that 
before the respective intervention [78]. In another clinical 
study enrolling 148 Chinese patients with histologically 
proven advanced or metastatic lung adenocarcinoma (stage 
IIIB or IV) and showing a complete or partial response to 
first-line therapy with the antifolate agent pemetrexed plus 
platinum of 4-6 cycles, were divided into an observation 
versus pemetrex maintenance group [79]. In the pemetrex 
maintenance group, significantly elevated serum miR-25 
levels were negatively correlated with progression-free 
survival time [79]. In contrast, serum miR-25 levels failed 
to correlate with progression-free survival time in the 
observation group [79].
Small cell lung cancer
Small cell lung cancer (SCLC) accounts for 
approximately 15% of all new lung cancer cases and has 
unique clinical and histological characteristics [80]. Zhao 
et al., similarly to that in NSCLC samples, reported the 
overexpression of miR-25 in human SCLC tissue samples 
and cell lines [80]. Interestingly, down-regulation of miR-
25 by antagomiR-25 treatment was shown to inhibit SCLC 
Figure 4: Repression of miR-25 in cancerous diseases. ATC: anaplastic thyroid cancer, CRC: colorectal cancer, NSCLC: non-small 
cell lung carcinoma, PC: prostate cancer. Gene symbols in bubbles are targets of miR-25 in multiple organs/diseases. Gene in red bubble 
is a target of miR-25 in multiple diseases.
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cell proliferation and induced the cell cycle arrest in the 
G1 phase possibly through the down-regulation of the cell 
cycle-related proteins cyclin E2 and CDK2. Cyclin E2 was 
shown to be a direct target of miR-25 in this study [80] 
(Table 4) (Figure 3).
Breast cancer
Breast cancer ranks the first among female cancers 
and is the second leading cause of death in women 
worldwide [81, 82]. Breast cancer is a heterogeneous 
disease entity, and numerous classification systems 
have been developed on the basis of histopathological 
and molecular genetic features or the appearance in 
imaging studies such as mammography or MRI [83]. 
From the point of view of therapy, both the stage/extent 
of the tumor and mentioned special features contribute 
to therapeutic decision. Breast cancer has always been 
managed more or less on an individual basis; the recent 
advances in precision medicine made a great impact on 
the management of breast cancer. Plenty of studies have 
examined the correlation between miRNA and mRNA 
expression in breast cancer and the role of miRNA 
expression profile in prognosis, but no clear conclusion 
has yet been reached [84]. The vast majority of studies 
investigating the role of miR-25 in the development of 
breast cancer have found that miR-25 was overexpressed 
in human breast cancer tissues and was elevated in the 
serum of patients [82, 84–90] (Table 5) (Figure 3). Hu 
et al. demonstrated in a two-stage case-control analysis 
that serum levels of miR-25, miR-16, miR-222 and miR-
324-3p were significantly upregulated as compared to 
those other miRNAs (miR-191 and miR-484) used as 
endogenous control in Chinese breast cancer patients 
[85] (Table 5). Wu reported that miR-25 expression was 
significantly higher in breast cancer patients based on data 
of 683 breast cancer tissues when compared to that in 87 
normal breast tissues according to The Cancer Genome 
Atlas [83]. Interestingly, another clinical study enrolling 
240 Norwegian early breast cancer patients showed strong 
and significant associations between the overexpression 
of miR-25, miR-18a/b, miR-106b, and miR-505 with high 
proliferation, estrogen receptor negativity and cytokeratin 
5/6 positivity of cancer [86] (Table 5). Moreover, using 
dataset analysis Farazzi et al. reported that miRNA 
families might control subtype-specific pathways in 
breast cancer and miR-25 showed high miRNA regulatory 
activity in triple-negative and basal-like subtypes of 
breast cancer [84]. Another study using 21 surgical breast 
cancer specimens revealed that increased expression of 
miR-25 was associated with high Ki-67 (a marker of cell 
proliferation) expression and HER2, ER and PR positivity 
[88] (Table 5). Interestingly, a study enrolling 76 breast 
cancer patients reported that overexpression of miR-25*, 
miR-142-3p, miR-505*, miR-1248, miR-181a-2*, and 
miR-340* could discriminate between tumor samples 
from BRCA1/2 mutation carriers and non-carriers [90]. 
A BRCA1/2A preclinical mechanistic study reported that 
down-regulation of miR-25 by isoliquiritigenin resulted 
in increased autophagic cell death by overexpression of 
ULK1 and induced chemosensitization in MCF7/ADR 
breast cancer cells [91] (Table 5) (Figure 3). Another 
study comprehensively analyzed tumor tissue miRNA 
expression and patient survival collecting data from the 
Cancer Genome Atlas (TCGA) which contains miRNA 
sequencing and overall survival datasets of 759 breast 
cancer patients [83, 89]. Surprisingly, this study found that 
increased expression of miR-25 predicted improved breast 
cancer survival [89].
Ovarian cancer
Ovarian cancer is the most common cause of 
gynecological malignancy-related mortality among 
women [92]. Epithelial ovarian cancer (EOC) accounts for 
approximately 90 % of ovarian tumors, including serous 
adenocarcinoma, endometrial adenocarcinoma and clear 
cell carcinoma [93]. Most cases are not diagnosed at an 
early stage [89]. Therefore, the 5-year survival rate is still 
poor despite advances in the diagnosis and chemotherapy 
[93, 94]. Studies investigating the expression of miR-
25 in epithelial ovarian cancer cell lines, tumorous 
tissues and serum from patients provided controversial 
findings. A preclinical study demonstrated that miR-25 
was overexpressed in human ovarian cancer cells and 
cell lines (SKOV3, OVCAR3, OVCAR5, and A2780) 
and ovarian surface epithelial cells (OSE) [92] (Table 5) 
(Figure 3). In this study, repression of miR-25 in ovarian 
cancer cells enhanced apoptosis by directly targeting 
Bim (also known as BCL2L11) [95]. Bim is also known 
as a direct activator of Bax and neutralizer of Bcl2-like 
molecules [95] (Table 5) (Figure 3). Another preclinical 
study showed that expression of miR-25 was increased in 
human ovarian cancer cells (OVCAR3, SKOV3, ES-2) 
[90] (Table 5) (Figure 3). In this study, inhibition of miR-
25 could suppress proliferation, migration, and invasion 
of ovarian cancer cells by directly targeting large tumor 
suppressor 2 (LATS2) [93] (Table 5) (Figure 3). A clinical 
cohort study enrolling 86 ovarian cancer patients reported 
that the increased expression of miR-25 in EOC tissue 
was associated with advanced clinical stage, lymph node 
metastasis and shorter survival time indicating that miR-
25 might be involved in carcinogenesis and metastasis of 
EOC [96] (Table 5). Moreover, another clinical cohort 
study recruiting 180 treated EOC patients and 66 healthy 
women from Germany showed that serum levels of miR-
25 was down-regulated after a median follow-up time 
of 21 months [97] (Table 5). Interestingly, Langhe et al. 
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Table 5: The role of miR-25 in breast, ovarian and prostate cancer
Disease
Species and 
tissue or cell 
type
Alteration 
of miR-25 
expression
Method 
for miR-25 
detection
Target gene Biological function
Method 
for target 
validation
Sample size 
in clinical 
studies
Ref.
1 BC human BS (Chinese)
up-
regulation
Solexa 
sequencing, 
Taqman low 
density array, 
qRT-PCR
N/A N/A N/A 24 BC vs.48 CONT [85]
2 BC
human BC 
tissue, human BS 
(Chinese)
up-
regulation
Solid 
sequencing, 
qRT-PCR
N/A N/A N/A 88 BC vs.60 CONT [82]
3 BC human BC tissue (dataset)
up-
regulation
qRT-PCR and 
dataset analysis N/A N/A N/A
683 BC vs.
87 CONT [91]
4 BC human BC tissue (Norwegian)
up-
regulation qRT-PCR N/A N/A N/A
240 BC 
(T1,2N0M0) [86]
5 BC human BC tissue (Japanese)
up-
regulation
Qiagen 
Human Cancer 
microRNA PCR 
Array system
N/A N/A N/A 21 BC [88]
6 BC
human BC cell 
line, NOD/SCID 
mice
up-
regulation
Affymetrix 
miRNA 3.0 
array, qRT-PCR
ULK1 autophagy LRA,WB N/A [81]
7 OVC
human OVC cell 
lines, ovarian 
surface epithelial 
cells
up-
regulation qRT-PCR BIM apoptosis
LRA, TF 
of miR 
mimics and 
antagomiR-25 
in vitro, WB
N/A [95]
8 OVC
human OVC 
cells, normal 
ovarian epithelial 
cell line
up-
regulation qRT-PCR LATS2
apoptosis, 
growth 
inhibition
LRA, miR-25 
mimics and 
antagomiR-25 
TF, WB
N/A [93]
9 OVC human OVC tissue (Chinese)
up-
regulation qRT-PCR N/A N/A N/A
86 OVC vs. 
ADJNTT [96]
10 OVC
human BS 
(German, 21 
months) human 
OVC cell lines
down-
regulation qRT-PCR N/A N/A N/A
180 OVC vs.
66 CONT [97]
11 OVC human BS (Irish) down-regulation qRT-PCR N/A N/A N/A
25 OVC vs.
25 CONT [92]
12 OVC
human BP 
(American, 15 
months)
down-
regulation qRT-PCR N/A N/A N/A 14 OVC [98]
13 PC
human PC tissue 
(American), 
MCM7 TG mice, 
nude mice (7 
wk), human PAC 
cell lines
up-
regulation 
of the miR-
106b-25 
cluster and 
MCM7
qRT-PCR PTEN
metastasis 
and 
invasion 
inhibitor
DLRA,
TF in vitro, 
WB
177 PC vs. 
ADJNTT [8]
(Continued )
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demonstrated that four circulating microRNAs including 
miR-25-3p let-7i-5p, miR-122, and miR-152-5p were 
significantly down-regulated in serous ovarian carcinoma 
patients as compared to benign serous cystadenoma 
patients in a small sample size clinical study (n=25) 
[92] (Table 5). In other tissues, miR-25 is known to 
target WNT signaling, and AKT/mTOR pathways which 
have previously been found to play a role in ovarian 
carcinogenesis and chemoresistance as well [92] (Table 
5). Moreover, Benson et al. reported that plasma miR-25 
expression was significantly decreased in chemotherapy-
resistant ovarian cancer patients, as compared to 
responders after 7 cycles of decitabine-carboplatin 
chemotherapy [98] (Table 5).
Prostate cancer
Prostate cancer (PC) is the second most common 
cancer among men worldwide [99]. Both early detection 
and therapy have significantly improved recently, 
however, about 25% of patients develop metastases. 
Prostate carcinoma may develop to a clinically aggressive 
form, which is resistant to androgen deprivation therapy, 
develops metastases and expresses neuroendocrine 
markers [100, 101]. A study has proven that the 
concomitant overexpression of the miR-106b-25 cluster 
and its host gene minichromosome maintenance protein 
7 (MCM7) cooperates in initiating prostate cancer by 
directly targeting the tumor suppressor phosphatase and 
tensin homologue (PTEN) gene both in prostate cancer 
cell lines and human prostate cancer specimens [8] (Table 
5) (Figure 3). PTEN has been shown to suppress the 
PI3K/Akt pathway which activates a number of target 
proteins to promote nutrient uptake, protein synthesis, cell 
survival, cell proliferation, cell motility and angiogenesis 
[8]. Furthermore, a study by Liang et al. demonstrated 
that hypoxia-induced neuronal and neuroendocrine 
differentiation of neuronal crest cells and PC cells by 
Disease
Species and 
tissue or cell 
type
Alteration 
of miR-25 
expression
Method 
for miR-25 
detection
Target gene Biological function
Method 
for target 
validation
Sample size 
in clinical 
studies
Ref.
14 PC human PC cell lines
up-
regulation 
of the miR-
106b-25 
cluster and 
MCM7
qRT-PCR PTEN
metastasis 
and 
invasion 
inhibitor
no N/A [102]
15 PC
human PC tissue, 
human PC cell 
lines, hypoxic 
neural crest cells
up-
regulation 
of the 106b-
25 cluster
qRT-PCR PTEN
metastasis 
and 
invasion 
inhibitor
anatgomiR-25 
or miR-25 TF 9 PC [101]
16 PC
prostate 
neuroendocrine 
cells, p53 knock 
down PC cells
up-
regulation qRT-PCR FBXW7
cell cycle 
arrest
RNA 
interference N/A [103]
17 PC
human PC tissue 
(Brazilian)human 
PC cell lines
up-
regulation qRT-PCR N/A N/A N/A 63 PC [104]
18 PC
human 
osteotropic 
PC cell lines, 
zebrafish 
embryos
down-
regulation qRT-PCR
ITGA6, 
ITGAV
metastasis 
and 
invasion
LRA,
miR-25 TF N/A [100]
19 PC human BP (Caucasian)
down-
regulation qRT-PCR N/A N/A N/A
68 PC vs.
79 CONT [106]
Abbreviations: ADJNTT: adjacent non-tumorous tissue, BP: blood plasma, BS: blood serum, BC: breast cancer, DLRA: dual luciferase 
reporter assay, IF: immunofluorescence, IH: immunohistochemistry, LRA: luciferase reporter assay, KO: knock out, OE: overexpression, 
OVC: ovarian carcinoma, PC: prostate cancer, TF: transfection, TG: transgene, WB: Western blot. The abbreviations in bold are 
considered as gold standard methods for miRNA target validation.
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inducing the miR-106b-25 cluster [101] (Table 5) (Figure 
3). In this study, overexpression of the miR-106b-25 
cluster resulted in the down-regulation of the tumor 
suppressor RE-1 silencing transcription factor (REST) 
[101] (Table 5) (Figure 3). Interestingly, REST has also 
been shown to be a negative regulator of PI3K/Akt 
pathway which is overactivated in PC [101]. Enterolactone 
produced by the metabolism of plant lignans by intestinal 
bacteria showed anti-proliferative effects in prostate 
cancer cell lines by repression of DNA licensing genes 
including MCM7 as well as the miR-106b-25 cluster, 
and overexpression of tumor suppressor gene PTEN 
[102] (Table 5). Interestingly, another mechanistic study 
by Li et al. showed that mutation of the p53 (TP53) 
tumor suppressor gene in prostate neuroendocrine cells 
could lead to overexpression of miR-25 similarly to the 
findings of Suh et al. in glioblastoma cells [64, 103] 
(Figure 3). This study by Li et al. demonstrated that the 
overexpression of miR-25 resulted in the repression 
of the E3 ubiquitin ligase FBXW7 leading to increased 
expression of its substrate Aurora kinase A (AURKA) 
which is a positive cell cycle regulator [103] (Table 5) 
(Figure 3). In contrast, Leite et al. found in advanced 
prostate cancer specimens (n=63) that the expression 
levels of several miRNAs including miR-25 significantly 
decreased during the progression of prostate cancer related 
to the transition from high grade prostate intraepithelial 
neoplasia to invasive adenocarcinoma, and the transition 
from localized to metastatic adenocarcinomas [104] 
(Table 5) (Figure 4). Moreover, Zoni et al. found that 
miR-25 was a negative regulator of the development of 
an invasive and metastatic phenotype in human prostate 
cancer cells by directly targeting the pro-invasive α6- and 
αv-integrins [100, 105] (Table 5). Indeed, a prospective 
clinical study enrolling 147 Caucasian age-matched 
patients with increased PSA levels and receiving needle 
biopsy to diagnose PC reported that decreased expression 
of miR-25-3p and other miRNAs correlated with increased 
malignancy [106] (Table 5). Interestingly, two clinical 
studies could not find any change in miR-25 expression 
in urine [107] or urine sediment samples [99] of prostate 
cancer patients.
Thyroid cancer
Thyroid cancer represents the most common 
malignant tumor originating from endocrine organ 
including 1) well-differentiated papillary thyroid 
carcinoma (PTC, 80%), 2) follicular thyroid carcinoma 
(15%), 3) poorly differentiated thyroid carcinoma (<1%) 
and 4) anaplastic thyroid carcinoma (<2%) [108]. The 
role of miR-25 in the development of different histologic 
types of thyroid cancer seems to be controversial. 
Mei et al. published that a pro-inflammatory and 
carcinogenesis promoting cytokine, interleukin-23 (IL-
23) could increase the expression of miR-25 in human 
thyroid cancer cell lines K1 (papillary type) and WRO 
(follicular type) promoting migration and invasion of 
thyroid cancer cells [109] (Table 6). This study also 
demonstrated that the overexpression of miR-25 directly 
reduced the expression of its direct target suppressor of 
cytokine signaling 4 (SOCS4) leading to increased IL-
23 expression in human thyroid cancer cell lines and 
tissue samples [109] (Table 6) (Figure 3). A clinical 
cohort study enrolling 56 patients with primary PTC, 
95 patients with benign thyroid nodules, and 10 age and 
gender-matched healthy controls from Northern China 
reported that plasma and tissue levels of miR-25-3p 
were significantly higher in PTC patients as compared 
to healthy controls or patients with benign thyroid 
nodules [108] (Table 6). In contrast, a research group 
found that miR-25 was repressed in anaplastic thyroid 
carcinoma using miRNA microarray [110] (Table 6) and 
qPCR for validation their results [111] (Table 6). They 
have also demonstrated that overexpression of miR-
25 by transfection into ACT-1, 8505c and FRO human 
anaplastic thyroid cell lines could inhibit proliferation 
and colony formation by directly targeting the oncogene 
polycomb protein enhancer of zeste 2 (EZH2) [111] 
(Table 6) (Figure 4). Parallel with the aforementioned 
results, another research group has also found that the 
expression of miR-25 was decreased in anaplastic thyroid 
carcinoma [112] (Table 6) in human tissue samples and 
cell lines [113] (Table 6). Transfection of miR-25 into 
8505c anaplastic thyroid cell line and Nthy-ori SV40-
immortalised thyroid cell line could directly reduce the 
expression of survival-promoting mitogen-activated 
protein kinase 4 (MEK4) and tumor necrosis factor-
related apoptosis inducing ligand (TRAIL) which could 
induce proliferation, migration, and invasion in tumor 
cells [113] (Table 6) (Figure 4).
Esophageal cancer
Esophageal cancer represents the eighth most 
common cancer and the sixth most common cause of 
tumorous death worldwide [114]. Esophageal cancer is 
developed from epithelial cells including two subtypes: 
1) esophageal adenocarcinoma (EAC) and 2) esophageal 
squamous cell carcinoma (ESCC) [114]. Mir-25 was 
unequivocally reported to be increased in both subtypes 
of esophageal cancer tissues and serum/plasma samples 
of patients.
Esophageal adenocarcinoma
Esophageal adenocarcinoma (EAC) is an aggressive 
type of esophageal cancer with an overall 5-year survival 
rate of <20% [115]. Barrett’s esophagus (BE) is a 
precursor abnormality of EAC [115]. In case of BE, the 
squamous epithelium of the esophagus is replaced by a 
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metaplastic, columnar-lined epithelium originating from 
the gastroesophageal junction [115]. The progression 
of BE to adenocarcinoma follows a series of histologic 
evolvement with an increasing progression rate [115]. 
These histologic events include 1) non-dysplastic Barrett’s 
metaplasia, 2) low-grade dysplasia (LGD), 3) high-grade 
dysplasia (HGD), and 4) adenocarcinoma [115]. Kan et 
al. demonstrated that increased level of miR-25 targeted 
and inhibited the translation of the pro-apoptotic Bim (also 
known as BCL2L11) in human EAC (OE-33) as well as 
metaplastic BE-derived cell lines (HEEpiC, QhTRT, 
ChTRT, GihTRT) and esophageal tissues (22 normal 
epithelia, 24 BE and 22 EAC) [116] (Table 7) (Figure 3). 
Zhang et al. had also reported increased miR-25 levels 
and decreased Bim expression in epithelial ovarian cancer 
cells similarly to the finding of the aforementioned study 
by Kan et al. in EAC [95, 116] (Figure 3). Moreover, the 
study by Kan et al. also reported that other elements of 
the miR-106b-25 cluster and its host gene, MCM7 were 
also overexpressed in EAC. These results are similar 
to the findings of Poliseno et al. in prostate cancer [8, 
116] (Figure 3). Indeed, a clinical study investigating 35 
normal epithelial, 34 BE, and 36 EAC tissues of American 
participants revealed that miR-25 and other miRNAs were 
overexpressed in BE and EAC samples with the most 
significant alteration in the BE metaplastic stage [115] 
(Table 7). Another clinical study using 119 tissue samples 
(24 normal/uninvolved mucosa samples from the distal 
esophagus of BE patients, 60 BE and 35 EAC) of Czech 
patients has also found that miR-25 and other miRNAs 
showed overexpression progressively in the sequence of 
normal mucosa, BE and EAC [117] (Table 7). Moreover, a 
clinical study enrolling Australian participants (19 healthy 
controls, 10 BE, and 18 locally advanced EAC patients) 
showed that a serum miRNA panel including miR-25 
and other miRNAs (RNU6-1/miR-16-5p, miR-25-3p/
miR-320a, let-7e-5p/miR-15b-5p, miR-30a-5p/miR-324-
5p, miR-17-5p/miR-194-5p) had enhanced specificity 
and sensitivity over single miRNA ratios to distinguish 
EAC from controls and BE [118] (Table 7). In addition, 
Table 6: The role of miR-25 in thyroid cancer
Disease
Species and 
tissue or cell 
type
Alteration 
of miR-25 
expression
Method 
for miR-25 
detection
Target gene Biological function
Method 
for target 
validation
Sample size in 
clinical studies Ref.
1 PTC/FTC
human PTC/FTC 
tissue (Chinese), 
human PTC/FTC 
cell lines
up-
regulation qRT-PCR SOCS4
metastasis and 
invasion
LRA,
RNA 
interference, 
WB
61 PTC/FTC vs. 
44 CONT [109]
2 PTC/FTC
human PTC/FTC 
tissue, human 
BP (Northern 
Chinese)
up-
regulation
Agilent Human 
miRNA 
microarray kit 
19.0
N/A N/A N/A 56 PTC vs.10 CONT [108]
3 ATC human ATC tissue (Italian)
down-
regulation
miRNA CHIP 
microarray, 
Northern blot
N/A N/A N/A 10 ATC vs.10 CONT [110]
4 ATC
human ATC 
tissue (French)
human thyroid 
epithelial cell 
lines
down-
regulation qRT-PCR EZH2 proliferation
DLRA,
WB N/A [111]
5 ATC human ATC tissue (Irish)
down-
regulation
Multiplex stem-
loop RT-PCR N/A N/A N/A
1 CONT, 2 classic 
PTC, 1 insular 
PTC, 2 ATC, 
1 lymphatic 
metastasis 
ATC, 1 vascular 
invasion ATC
[112]
6 ATC
human ATC 
cell line 
(Irish), human 
immortalized 
thyroid cell line
down-
regulation qRT-PCR
MEK4, 
TRAIL
proliferation, 
apoptosis WB N/A [113]
Abbreviations: ATC: anaplastic thyroid cancer, BP: blood plasma, DLRA: dual luciferase reporter assay, IF: immunofluorescence, IH: 
immunohistochemistry, LRA: luciferase reporter assay, KO: knock out, OE: overexpression, PTC/FTC: papillary thyroid carcinoma/follicular thyroid 
carcinoma, TF: transfection, TG: transgene, WB: Western blot. The abbreviations in bold are considered as gold standard methods for miRNA target 
validation. 
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Table 7: The role of miR-25 in gastrointestinal tumors
Disease
Species and 
tissue or cell 
type
Alteration 
of miR-25 
expression
Method for miR-
25 detection Target gene
Biological 
function
Method for 
target validation
Sample size in 
clinical studies Ref.
1 EAC/BE
human EAC 
and BE cell 
lines, human 
EAC tissues 
(American)
up-regulation 
of the miR-
106b-25 cluster 
and MCM7
Applied 
Biosystem 
Taqman 
MicroRNA assay 
(human),  
qRT-PCR
BIM apoptosis LRA,WB
22 CONT 
epithelia, 24 
BE, 22 EAC
[116]
2 EAC/BE
human EAC 
and BE tissue 
(American)
up-regulation
Applied 
Biosystems’ real-
time PCR-based 
TaqMan Human 
Micro-RNA Card 
Set v3.0 for 754 
miRNAs
N/A N/A N/A
35 CONT 
epithelia, 34 
BE, 36 EAC
[115]
3 EAC/BE human EAC and BE tissue (Czech) up-regulation
Affymetrix 
GeneChip miRNA 
3.0 arrays
N/A N/A N/A 24 ADJNTT, 60 BE, 35 EAC [117]
4 EAC/BE human BS (Australian) up-regulation
TaqMan 
OpenArray 
Human 
microRNA panel 
for 758 miRNAs
N/A N/A N/A 19 CONT, 10 BE, 18 EAC [118]
5 EAC/BE human BS (American) up-regulation
Solexa deep 
sequencing for 
small RNAs,
qRT-PCR
N/A N/A N/A 10 EAC vs. 11 CONT [119]
6 ESCC
human ESCC 
cell lines, human 
ESCC tissue 
(Chinese)
up-regulation qRT-PCR CDH1
metastasis 
and invasion 
inhibitor
LRA, WB N/A [114]
7 ESCC
human ESCC 
cell lines, human 
ESCC tissue 
(Chinese)
up-regulation qRT-PCR DSC2
metastasis 
and invasion 
inhibitor
LRA, WB 124 ESCC [121]
8 ESCC
human ESCC 
tissue (Northern 
Chinese)
up-regulation qRT-PCR N/A N/A N/A 5 ESCC [122]
9 ESCC
human ESCC 
tissue, BS 
(Chinese)
up-regulation qRT-PCR N/A N/A N/A
20 ESCC vs. 
20 CONT 
tissue, 
194 ESCC vs.
94 CONT 
serum
[72]
10 ESCC human BS (Chinese) up-regulation
Taqman low 
density array, 
qRT-PCR
N/A N/A N/A 111 ESCC [123]
11 ESCC human BP (Japanese) up-regulation
3D-Gene miRNA 
microarray, qRT-
PCR
N/A N/A N/A 105 ESCC vs.50 CONT [120]
12 GC human GC cell lines
up-regulation 
of the miR-
106b-25 cluster 
and MCM7
miRNA 
microarray chips 
(V2) for 250 
human miRNAs, 
qRT-PCR,
Northern blot
BIM, p21 apoptosis cell cycle arrest LRA, WB N/A [125]
(Continued)
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Disease
Species and 
tissue or cell 
type
Alteration 
of miR-25 
expression
Method for miR-
25 detection Target gene
Biological 
function
Method for 
target validation
Sample size in 
clinical studies Ref.
13 GC human GC cell lines
up-regulation 
of the 106b-25 
cluster and 
MCM7
qRT-PCR Col1a2, p53
metastasis 
and invasion 
inhibitor, 
apoptosis, cell 
cycle arrest
antagomiR-25 
TF, IF N/A [127]
14 GC
human GC tissue 
and human BP 
(Chinese), human 
GC cell lines, 
nude mice
up-regulation qRT-PCR TOB1 growth inhibitor
LRA, 
antagomiR-25 TF, 
WB
103 GC vs. 
80 CONT [126]
15 GC
human GC tissue 
(Chinese, 80 
months), human 
GC cell lines, 
nude mice
up-regulation qRT-PCR FBXW7 cell cycle arrest
LRA, 
antagomiR-25 
TF in vitro and in 
vivo, WB
40 GC vs. 
ADJNTT [129]
16 GC
human GC tissue 
and human BP 
(Chinese), human 
GC cell lines
up-regulation qRT-PCR LATS2
apoptosis 
growth 
inhibition
DLRA, 
antagomiR-25 
and miR-25 TF
14 GC vs. 
14 CONT [131]
17 GC
human GC tissue 
(Chinese), human 
GC cell lines
up-regulation qRT-PCR RECK
metastasis 
and invasion 
inhibitor
LRA, 
antagomiR-25 
and miR-25 TF, 
WB
27 GCs [132]
18 GC
human GC tissue 
and human BP 
(Chinese)
up-regulation 
of the miR-
106b-25 cluster
qRT-PCR N/A N/A N/A 40 GC vs. ADJNTT [130]
19 GC human BP (Chinese) up-regulation
Taqman low 
density array, 
qRT-PCR
N/A N/A N/A
160 CONT, 
124 GNCA, 
36 GCA
[135]
20 GC human BP (Chinese) up-regulation
Exiqon 
miRCURY ready 
to use PCR 
human panel- 
I+II-V.M for 168 
miRNAs
N/A N/A N/A 133 GC vs. 109 CONT [134]
21 GC
human GC 
tissue (EPIC-
EURGAST 
study)
up-regulation 
of the miR-
106b-25 cluster
Applied 
Biosystems Big 
Dye Terminators 
Cycle Sequencing 
Kit
N/A N/A N/A 365 GC vs. 1284 CONT [124]
22 GC human GC tissue (Korean) up-regulation qRT-PCR N/A N/A N/A
91 GC vs. 
26 CONT [143]
23 CRC human CC cell lines up-regulation
ArrayExpress 
microRNA 
microarray chip, 
qRT-PCR
MCU apoptosis LRA, IF N/A [138]
24 CRC human BS (Chinese)
up-regulation 
of the miR-
106b-25 cluster
qRT-PCR N/A N/A N/A 66 CRC vs. 86 CONT [139]
25 CRC human CRC tissue (Japanese)
up-regulation 
of the miR-
106b-25 cluster
Agilent miRNA 
microarray, Early 
Access Version,
qRT-PCR
N/A N/A N/A 13 CRC vs. 4 CONT [141]
(Continued)
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a small sample size American study using 10 EAC (stage 
I-III) and 11 healthy control serum samples also verified 
that serum level of miR-25 was elevated in EAC [119] 
(Table 7).
Esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC) 
is the predominant histological subtype of esophageal 
carcinomas in Asian countries accounting for 
approximately 90% of all esophageal tumors [120]. 
The prognosis is very poor due to early invasion and 
metastasis via the well-developed network of submucosal 
lymphatic vessels [115]. Xu et al. reported that the up-
regulation of miR-25 in ESCC samples of Chinese 
patients significantly correlated with the presence of 
lymph node metastases and advanced TNM stage [114]. 
In this study, miR-25 directly targeted E-cadherin 
(CDH1) and inhibited its metastasis suppressor 
function and promoted cell migration and invasion in 
human ESCC cell lines (KYSE-150 and KYSE-410) 
[114] (Table 7) (Figure 3). Fang et al. demonstrated 
that miR-25 could down-regulate desmocollin-2 
(DSC2) in human ESCC cell lines (EC109, KYSE150, 
KYSE180 and SHEEC) [121] (Table 7) (Figure 3). The 
repression of DSC2 was proposed to increase the level 
of free γ-catenin. It competes with β-catenin to form a 
complex with E-cadherin [121]. This competition might 
subsequently cause an increase in free cytoplasmic 
β-catenin level leading to its enhanced nuclear transport 
and transcriptional activity. This activates invasion-
associated gene expression and ESCC invasion [121]. 
Zhu et al. found in 5 North Chinese ESCC patients that 
miR-25 was significantly overexpressed in ESCC tissues 
as compared to normal basal or differentiated cells [122] 
(Table 7). A clinical study enrolling 194 ESCC patients 
and 94 healthy volunteers in China showed that miR-25 
was overexpressed both in serum and tissue samples of 
ESCC patients [123] (Table 7). The overexpression of 
miR-25 was associated with lymph node metastasis [123] 
(Table 7). Another clinical study recruiting 111 Chinese 
ESCC patients confirmed that miR-25 was overexpressed 
in serum and tissue samples of ESCC patients [123] 
(Table 7). However, overexpression of miR-25 showed 
a positive correlation with overall survival in this study 
[123] (Table 7). Moreover, a third clinical study enrolling 
105 Japanese ESCC patients and 50 healthy controls 
also reported that miR-25 level was significantly higher 
in plasma and tissues samples of ESCC patients [119] 
(Table 7). Plasma miR-25 levels were significantly 
reduced in postoperative samples as compared to those 
preoperatively, while increased again if ESCC recurred 
[119] (Table 7).
Gastric cancer
Gastric cancer (GC) ranks the second among 
cancer-related mortality causes [124]. Over 95% of 
gastric tumors are adenocarcinomas [125]. Proximal and 
distal gastric adenocarcinomas are the two main clinical 
manifestations of GC [124]. Histologically, there are 
two major types: 1) intestinal type presenting clearly 
defined glandular structures (54% of cases) and 2) 
diffuse type adenocarcinoma consisting of individually 
infiltrating neoplastic cells (32% of cases) [124, 126]. In 
addition, there is an indeterminate type as an uncommon 
variant (15% of cases) [124, 126]. Interestingly, the 
highest incidence of GC is frequently found in Eastern 
Asia especially in China, Eastern Europe and South 
America, and the lowest in North America and most 
parts of Africa [126]. A number of studies found 
unequivocally that miR-25 is overexpressed in human 
GC cell lines, tissue and serum/plasma samples as well. 
A mechanistic study by Petrocca et al. found that E2F1 
(also called retinoblastoma binding protein 3) induced 
the overexpression of the miR-106b/25 cluster via 
its host gene MCM7 [125] (Table 7). Moreover, miR-
Disease
Species and 
tissue or cell 
type
Alteration 
of miR-25 
expression
Method for miR-
25 detection Target gene
Biological 
function
Method for 
target validation
Sample size in 
clinical studies Ref.
26 CRC human CRC tissue (Chinese) up-regulation qRT-PCR N/A N/A N/A
186 CRC vs.
18 CONT [140]
27 CRC
human CRC 
tissue (Chinese), 
BALB/c-nu nude 
mice, human 
CRC cell line
down-regulation qRT-PCR SMAD7
proliferation, 
metastasis and 
invasion
LRA, miR-25 TF, 
WB
20 CRC vs. 
ADJNTT [142]
Abbreviations: ADJNTT: adjacent non-tumorous tissue, BP: blood plasma, BS: blood serum, CAC: cholangiocarcinoma, CONT: control, CRC: colorectal 
cancer, DLRA: dual luciferase reporter assay, EAC/BE: esophageal adenocarcinoma/Barrett esophagus, ESCC: esophageal squamous cell carcinoma, GC: 
gastric cancer, GCA: gastric cardia adenocarcinoma, GNCA: gastric non-cardia adenocarcinoma, IF: immunofluorescence, IH: immunohistochemistry, 
LRA: luciferase reporter assay, KO: knock out, OE: overexpression, TF: transfection, TG: transgene, WB: Western blot. The abbreviations in bold are 
considered as gold standard methods for miRNA target validation.
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106b and miR-93 could control E2F1 by a negative 
feedback loop that might be important in preventing 
E2F1 self-activation and, possibly, apoptosis [125] 
(Table 7) (Figure 3). In addition, overexpression of the 
miR-106b/25 cluster resulted in a decreased response of 
gastric cancer cells to TGFβ interfering with the synthesis 
of cell cycle inhibitor p21 (also called CDKN1A) and the 
pro-apoptotic Bim (also called BCL2L11)[125] (Table 
7) (Figure 3). Interestingly, another study using human 
gastric cell lines also reported that the amplification 
of MCM7 and its intron miR-25 might be the major 
molecular switchers in the development of gastric cancer 
[127]. This study reported that MCM7 and miR-25 were 
able to suppress the adjacent gene, collagen type I alpha 
2 chain (Col1a2) as well as the tumor suppressor p53 
and activate the proto-oncogene tyrosine-protein kinase 
c-Src gene in human GC cell lines [127]. Li et al. showed 
overexpression of miR-25 in plasma and tissue samples 
of GC patients which promoted gastric cancer migration, 
invasion and proliferation by directly targeting the tumor 
suppressor TOB1 (also known as transducer of ERBB2, 
1 or transducer of Her1/2) and correlated with poor 
survival [126] (Table 7) (Figure 3). In contrast, a single 
nucleotide polymorphism rs41274221 in the mature 
miR-25 gene was associated with reduced tumor growth 
and metastasis in GC patients [128]. In this study, the 
overexpression of miR-25 with AA genotype resulted 
in the reduced ability of binding on the direct target 
TOB1 mRNA as compared with GG or GA phenotypes 
[128] (Table 7) (Figure 3). The reduced binding ability 
of mir-25 resulted in protective effects in gastric cancer 
cell lines in this study [128] (Table 7) (Figure 3). Others 
demonstrated that overexpression of miR-25 promoted 
cell proliferation, invasion and migration by directly 
down-regulating the tumor suppressor E3 ubiquitin 
ligase FBXW7 and up-regulating its substrates including 
G1/S-specific cyclin E1 (CCNE1) and v-myc avian 
myelocytomatosis viral oncogene homolog (MYC) in 
human GC samples and cell lines [129, 130] (Table 7) 
(Figure 3). It was also reported that miR-25 and miR-
107 could simultaneously reduce the expression of large 
tumor suppressor 2 (LATS2) gene promoting cell growths 
and invasion in human gastric cancer cell lines [131] 
(Table 7) (Figure 3). Zhao et al. published that miR-
25 may directly target the tumor suppressor reversion-
inducing-cysteine-rich protein with kazal motifs (RECK) 
inducing cell growth and motility in human GC tissues 
and cell lines [132] (Table 7) (Figure 3). RECK has 
been reported to suppress matrix metalloproteinases 
including MMP-2, MMP-9, and MMP-14 which are also 
involved in angiogenesis and cancer progression related 
breakdown of the extracellular matrix [132]. Clinical 
studies have also found that miR-25 is elevated in tissue 
and/or plasma/serum samples of GC patients (stage I-III) 
from China [133–136], Korea [137] and Europe [124] 
(EPIC-EURGAST study).
Colorectal cancer
Colorectal cancer is the second most common 
cancer among men and women worldwide. Mir-25 
has been shown to directly target an important factor 
in inflammatory carcinogenesis, the angiopoietin-like 
protein 2 and the mitochondrial calcium uptake regulating 
mitochondrial calcium uniporter in cells and colorectal 
carcinoma cell lines (Table 7) (Figure 3) [138]. Clinical 
studies have also found that miR-25 is overexpressed in 
colorectal cancer tissue and serum samples of Chinese 
[139, 140] and Japanese patients [141] showing correlation 
with TNM stage and patient prognosis [140] (Table 7). In 
contrast, Li et al. found that miR-25 was downregulated 
and its direct target Smad7 – a TGF-β type 1 receptor 
superfamily member - was upregulated in human 
colorectal cancer tissue samples of Chinese patients [142] 
(Table 7) (Figure 4).
Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the third most 
common cause of cancer-related mortality with the 
highest incidence in Asia and Africa [143]. A number 
of studies have unequivocally shown overexpression of 
miR-25 and the miR-106b/25 cluster in HCC cell lines, 
clinical HCC tissue, and serum samples. Mir-25 has 
been reported to reduce apoptosis by directly targeting 
the pro-apoptotic Bim (also known as BCL2L11) in 
human liver cell lines and HCC tumor tissues [144]. 
MiR-25 has also reduced the expression of TNF-related 
apoptosis-inducing ligand (TRAIL) via the PTEN/PI3K/
Akt/Bad axis in liver cancer stem cells [145], human 
cholangiocarcinoma cell lines, and tissue samples [146] 
(Table 8) (Figure 3). Bim has also been shown to be a 
direct target of miR-25 in ovarian cancer, esophageal 
adenocarcinoma, and gastric cancer. Overexpression 
of miR-25 and reduction of TRAIL-induced apoptosis 
has also been associated with thyroid cancer [147]. 
Interestingly, WNT/beta-catenin pathway was reported 
to induce miR-25 expression leading to the repression 
of its direct target RhoGDI1 and overexpression of the 
epithelial-mesenchymal transition inducing SNAIL in 
HCC cell lines and human HCC tissues [148] (Table 8) 
(Figure 3). Another study using hepatoma and normal 
hepatic cell lines demonstrated that miR-25 gene and 
other 4 miRNA genes were in hypomethylation status 
and these miRNAs were also upregulated in HCC [149] 
(Table 8) (Figure 3). Overexpression of the miR-106b-25 
cluster and repression of its direct target retinoblastoma 
1 (RB1) oncogene and histone acyltransferase (KAT2b) 
were also reported in regenerating liver after 2/3 
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Table 8: The role of miR-25 in hepatocellular carcinoma
Disease
Species and 
tissue or cell 
type
Alteration 
of miR-25 
expression
Method 
for miR-25 
detection
Target 
gene
Biological 
function
Method 
for target 
validation
Sample 
size in 
clinical 
studies
Ref.
1 HCC
human 
HCC tissues 
(Asian), 
human HCC 
cell cultures
up-regulation 
of the miR-
106b-25 cluster
qRT-PCR BIM, E2F1
apoptosis, 
cell cycle 
arrest
LRA, 
antagomiR-25 
TF, WB
55 HCC vs. 
ADJNTT [145]
2 HCC liver cancer stem cells up-regulation qRT-PCR PTEN
metastasis 
and invasion 
inhibitor
antagomiR-25 
TF N/A [146]
3 HCC
human 
HCC tissue 
(Chinese), 
human HCC 
cell lines
up-regulation qRT-PCR RhoGDI1
metastasis 
and invasion 
inhibitor
LRA, WB, 
miRNA or 
siRNA TF, IF
35 HCC vs. 
ADJNTT [148]
4 HCC human HCC cell lines up-regulation MeDip chip N/A N/A bioinformatics N/A [150]
5 HCC
human 
HCC tissue 
(Chinese)
up-regulation qRT-PCR N/A N/A N/A
133 
HCC vs. 
ADJNTT
[153]
6 HCC(HBV, HCV)
human BS 
(Chinese) up-regulation
Solexa 
sequencinq,
RT-PCR
N/A N/A N/A
210 CONT, 
135 HBV,
48 HCV,
120 HCC
[154]
7 HCC (HBV) human BS (Chinese) up-regulation qRT-PCR N/A N/A N/A
23 HBV 
pos. HCC, 
20 liver 
cirrhosis, 
20 chronic 
hepatitis B, 
16 CONT
[149]
8 HCC (HBV)
human HBV 
pos. HCC 
tissue human 
BP (Chinese)
up-regulation
Taqman 
low density 
array,  
qRT-PCR
N/A N/A N/A
50 HCC vs. 
37 cancer 
free HBV 
pos.
[156]
9 HCC (HBV)
human 
HBV pos. 
HCC tissue 
(Chinese), 
human HCC 
cell lines
up-regulation 
of the miR-
106b-25 cluster 
and MCM7
qRT-PCR N/A N/A N/A
120 
HCC vs. 
ADJNTT
[157]
10 HCC human HCC cells
up-regulation 
of the miR-
106b-25 cluster
Northern 
blot N/A N/A N/A N/A [144]
11 CAC
human 
CAC tissue 
(American), 
human CAC 
cell lines
up-regulation qRT-PCR TRAIL apoptosis LRA,IF
15 CAC vs.
4 CONT [147]
Abbreviations: ADJNTT: adjacent non-tumorous tissue, BS: blood serum, CAC: cholangiocarcinoma, CONT: control, DLRA: dual 
luciferase reporter assay, HBV: hepatitis B virus, HCC: hepatocellular carcinoma, HCV: hepatitis C virus, IF: immunofluorescence, 
IH: immunohistochemistry, LRA: luciferase reporter assay, KO: knock out, OE: overexpression, TF: transfection, TG: transgene, WB: 
Western blot. The abbreviations in bold are considered as gold standard methods for miRNA target validation.
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partial hepatectomy [150] (Table 8) (Figure 3). This 
observation might have clinical translational value in 
the renewal of HCC because partial hepatectomy is a 
commonly performed operation to treat hepatic tumors. 
Another study reported that miR-25 directly repressed 
cytochrome P450 2B6. This member of the cytochrome 
P450 family is responsible for the metabolism of nearly 
25% of drugs including several anticancer agents (e.g., 
tamoxifen, cyclophosphamide, and iphosphamide, etc.) 
[151] (Table 8) (Figure 3).
A clinical study enrolling 131 Chinese HCC 
patients has reported that overexpression of miR-25 in 
human HCC tissue showed a negative correlation with 
overall survival [152] (Table 8). Another study recruiting 
513 subjects from China showed that elevation of miR-
25 in blood serum could be a biomarker of HCC [153] 
(Table 8). Another cohort study enrolling Chinese 
patients with HBV-related small HCC (23 cases), liver 
cirrhosis (20 cases), chronic hepatitis B (20 cases) and 
healthy controls (16 cases) has found that serum miR-25 
could be a potential biomarker not only of HBV-related 
HCC but also of liver cirrhosis and chronic hepatitis B 
infection [149] (Table 8). Interestingly, clinical studies 
reported that increased levels of circulating miR-25 were 
positively correlated with liver diseases in children with 
cystic fibrosis as well [154] (Table 8). Additional studies 
reported that the miR-106b-25 cluster or miR-25 alone 
was overexpressed in HBV positive HCC tissue and serum 
samples [149, 155, 156] (Table 8). Moreover, transfection 
of human HCC cells with hepatitis B virus X protein 
resulted in overexpression of the miR-106b-25 cluster and 
its host gene MCM7 [157] (Table 8).
Figure 5: MiR-25 acts as a double-edged sword in the development of diverse diseases. ATC: anaplastic thyroid cancer, 
CAC: cholangiocarcinoma, CNS: central nervous system, CRC: colorectal cancer, DNP: diabetic nephropathy, EAC/BE: esophageal 
adenocarcinoma/Barrett esophagus, GC: gastric cancer, GBM: glioblastoma multiforme, HCC: hepatocellular carcinoma, LVH: left 
ventricular hypertrophy, HF: heart failure, I/R: ischemia/reperfusion, NSCLC: non-small cell lung carcinoma, OVC: ovarian cancer, PAH: 
pulmonary arterial hypertension, PC: prostate cancer. Genes in red bubbles are targets of miR-25 in multiple organs/diseases.
Oncotarget21605www.oncotarget.com
CONCLUSIONS
In the past decade, a growing body of evidence 
showed that miRNAs are key regulators of different 
human diseases. These miRNAs could be potentially new 
therapeutic targets in the future. MiR-25 is expressed 
in a wide variety of tissues and cell types targeting 
many mRNAs. In this review, we have shown that both 
overexpression and repression of miR-25 could result 
in the development of different diseases (Figure 5). 
Expressional change of miR-25 seems to act as a double-
edged sword in case of three target mRNAs including p57, 
SERCA2, and TRAIL. Overexpression or repression of 
these target mRNAs causes different diseases in the same 
(p57) or different tissues (SERCA2 and TRAIL) (Figure 
5). Moreover, there are common target mRNAs of miR-
25 in different tissue and cell types regulating the same 
biological process. The expressional changes of these 
common target mRNAs could result in different diseases 
sharing common general pathomechanisms (e.g., NOX4 
regulating oxidative stress in heart and kidney diseases, 
Col1a2 in myocardial fibrosis and tumor metastasis, BIM 
in different cancer types, etc.) (Figure 5). Therefore, long-
term miR-25 based therapy seems to be possible in the 
diseased target cells. Nevertheless, potentially harmful 
effects of miR-25 based drugs (antagomiR-25 or miR-
25 mimic) could originate not only from off-target side 
effects (unwanted gene expression changes or chemical 
toxicity) but also could result from on-target side effects 
in non-targeted and non-diseased tissues.
On the other hand, different molecular mechanisms 
may lead to the development of a specific disease 
and these molecular mechanisms could be regulated 
by different miRNAs. Therefore, miRNAs could be 
diagnostic and prognostic biomarkers of certain diseases. 
MiR-25 seems to be an important biomarker in cancerous 
diseases, however, expressional level of miR-25 alone 
does not seem to be sufficient to set up diagnosis or 
assess disease progression. Expressional change of miR-
25 among a specific set of miRNAs or other biomarkers 
might be more reliable in the diagnosis or prognosis of a 
specific disease, however, validation of the usefulness of 
such diagnostic panels still need to be done.
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